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  28 
ABSTRACT 29 
Although death is inevitable, individuals have long sought to alter the course of the ageing 30 
process. Indeed, ageing has proved to be modifiable; by intervening in biological systems such 31 
as nutrient-sensing, cellular senescence, the systemic environment and the gut microbiome, 32 
phenotypes of ageing can be slowed sufficiently to mitigate age-related functional decline. 33 
These interventions can also delay the onset of many disabling, chronic diseases, including 34 
cancer, cardiovascular disease and neurodegeneration in animal models. Here we examine the 35 
most promising interventions to slow ageing and group them into two tiers based on the 36 
robustness of the preclinical, and some clinical, results, in which the top tier includes 37 
rapamycin, senolytics, metformin, acarbose, spermidine, NAD+ enhancers and lithium. We 38 
then focus on the potential of the interventions and the feasibility of conducting clinical trials 39 
with these agents, with the overall aim of maintaining health for longer before the end of life. 40 
  41 
[H1] Introduction 42 
Research into ageing is still a small field relative to mature areas, including those focused on 43 
major age-related diseases. Publications on cancer, cardiovascular disease (CVD) and 44 
Alzheimer’s Disease greatly outstrip those on ageing and gerontology. However, advancing 45 
age is the major risk factor for all of these diseases, and recent events have conspired to bring 46 
the rapidly expanding field of research into ageing to the forefront. First, global demographic 47 
changes are dramatically altering the age-structure of humans. For instance, a combination of 48 
longer lives and declining birth rates has resulted in more people over the age of 65 than under 49 
5, and this trend will continue, with many countries facing a deluge of elders (FIG. 1a). 50 
Healthspan [G] has not kept up with increasing lifespan and, since ageing is the predominant 51 
risk factor for most chronic diseases1-3 (FIG. 1b), the greying population is increasingly 52 
threatening economic growth and sustainability, with the healthcare sector particularly 53 
vulnerable4,5. Second, the pharmaceutical sector has spent large amounts of time and resource 54 
on development of treatments for age-related chronic disease, with only limited success. Some 55 
conditions, for instance neurodegenerative diseases6,7, remain largely refractory to treatment 56 
and most others can, at best, be delayed. Third, research from animal models, including 57 
mammals, has demonstrated that delayed ageing and extended longevity are feasible3,8-11 and, 58 
more importantly, are often associated with an extension of healthspan12-17. Similar success in 59 
humans would improve life quality by preserving functional capacity with age and decreasing 60 
disease burden across a wide spectrum of age-related conditions, and would result in dramatic 61 
savings in healthcare costs18,19.  62 
 63 
Strategies for combating mechanisms of ageing to prevent disease, known as ‘geroprotection’, 64 
are far reaching, and currently include recommendations for exercise, diet and other aspects of 65 
lifestyle. However, these alone are not sufficient to prevent the ills of old age, and increasing 66 
efforts are directed to tackling the underlying processes of ageing3. The results of these 67 
processes include damage to the genetic material and its packaging and expression, cellular 68 
senescence, and dysregulated proteostasis, mitochondrial function, nutrient-sensing, 69 
intercellular communication and stem cell function20. These hallmarks of ageing are casually 70 
connected, and they interact with one another to produce ageing-related decline. Currently, the 71 
most promising strategies for geroprotection include mildly lowering the activity of the 72 
nutrient-sensing network, especially the activity of mechanistic target of rapamycin protein 73 
complex 1(mTORC1), removing senescent cells, using natural metabolites from the systemic 74 
environment that can rejuvenate stem cells and transferring the microbiome. Increasing 75 
autophagy, probably including mitophagy, and reducing age-related inflammation are 76 
emerging as key mechanisms by which these interventions exert their effects. The private 77 
sector has entered the fray in a large way in recent years, with dozens of companies exploring 78 
strategies to target these hallmarks of ageing21. An important strategy is the development of 79 
small molecules, both drugs and natural products, that have geroprotective effects by 80 
combating the mechanisms of ageing (FIG. 2). A major theme here is the prospect for 81 
indication expansion, where small molecules and agents that have good safety profiles and 82 
were previously identified for other properties are candidates for repurposing as 83 
geroprotectors22,23. 84 
 85 
Several hundreds of potential geroprotectors have been reported to modulate ageing in one or 86 
more species (see recent reviews24-33 for more complete lists). Here, we review a select list of 87 
agents grouped as Tier1 or Tier 2 that, in our view, are the most developed experimentally and 88 
nearest to clinical testing, or intriguing based on information linked to mechanisms of ageing20. 89 
To select these agents, we used a set of geroprotector criteria modified from a recent review26 90 
(BOX 1). Tier 1 agents meet the primary and most of the secondary criteria and are generally 91 
robust in ageing studies. Meanwhile, Tier 2 compounds are comprised of mature agents that 92 
either meet fewer criteria or have generated conflicting data as to their effect on ageing, and 93 
emerging compounds that show strong promise, but are immature from the perspective of drug 94 
development, at least for targeting ageing. We highlight the mechanisms of ageing that have 95 
so far been shown to be targeted by these compounds and the strength of the evidence for their 96 
geroprotective effects (FIG. 2). Shedding light on these geroprotective mechanisms will likely 97 
implicate further agents, including new chemical entities, from chemical screens (BOX 2) and 98 
in silico approaches (BOX 3) that outperform the compounds reviewed here.  99 
 100 
Human ageing may be modifiable and research into ageing is entering a new and exciting phase 101 
where interventions to extend healthspan will be tested in humans and, if validated, potentially 102 
approved for use in humans. In addition to making the case for clinical testing of a select set of 103 
agents, we also discuss potential routes to testing the effects of candidates on human ageing 104 
and, if these are successful, how they could be employed to enhance human healthspan. 105 
 106 
[H1] Tier 1 107 
[H2] Rapamycin and mTOR inhibitors 108 
Rapamycin is a macrolide compound, first discovered in 1960 as an antifungal agent isolated 109 
from bacteria in an Easter Island (Rapa Nui) soil sample. It was subsequently found to have 110 
immunosuppressive and antiproliferative properties in mammalian cells34,35. Rapalogs 111 
(Sirolimus and its derivatives) are used as immune modulators to prevent organ transplant 112 
rejection, as cancer chemotherapeutics, and to prevent restenosis after cardiac surgery36,37. 113 
Rapamycin binds to FK-506 binding protein 12 (FKBP12), creating a trimolecular complex 114 
with mTOR. This rapamycin-FKBP12 binding event leads to destabilization, and thus 115 
inhibition, of mTORC1, a central regulator of cell and organismal physiology. mTORC1 116 
integrates growth factors, nutrition, stress and other inputs to phosphorylate numerous targets, 117 
and modulates cellular processes including autophagy, ribosome biogenesis, protein synthesis 118 
and turnover, metabolism of lipids, nucleotides and glucose, as well as cell growth.  119 
 120 
Genetic and pharmacological inhibition of mTORC1 activity can increase lifespan in budding 121 
yeast38-40, Caenorhabditis elegans41-44 and Drosophila melanogaster42,45. An ageing research 122 
milestone occurred with publications from the NIA Intervention Testing Program (ITP) (BOX 123 
4) showing that rapamycin extended both median and maximum lifespan of genetically 124 
heterogeneous mice when administered starting at either 9 or 20 months of age46,47. It is striking 125 
that rapamycin treatment can affect longevity even when initiated at 20 months, equivalent to 126 
about age 65 in humans, and perhaps even more surprising that a three-month treatment 127 
between 20 and 23 months is also sufficient to extend lifespan by up to 60%, based on the 128 
remaining lifespan of the animals14. An even shorter six week treatment initiated at the same 129 
age can also delay ageing48. Notably, and unlike several other interventions, rapamycin has 130 
been reported to extend lifespan in multiple mouse strains. Finally, genetic modulation of 131 
mTOR signaling can ameliorate ageing in many organisms including mice49. 132 
 133 
Rapamycin not only extends lifespan, but healthspan as well. As a potent anti-cancer agent50-134 
53, it was proposed that rapamycin extends lifespan solely through an anti-tumour mechanism, 135 
suppressing a major pathology in mouse strains54,55. However, recently, widespread testing of 136 
rapamycin’s effects has led to the general conclusion that rapamycin has much broader effects 137 
on healthspan. Multiple age-related changes in mice have been reported to be slowed or even 138 
reversed by rapamycin treatment, including changes in arterial structure and function56, 139 
cognitive defects57,58, cardiac hypertrophy and diastolic dysfunction59,60, periodontitis61, 140 
duration of ovarian function62, immune senescence48, multifocal macrovesicular lipidosis in 141 
the liver, abnormalities of nuclear size and chromatin conformation in the myocardium, 142 
endometrial cystic hyperplasia, adrenal tumours, decline in spontaneous activity and loss of 143 
elasticity in tendons55. However, cataract severity and testicular degeneration are increased55. 144 
It should be noted that one study, in which rapamycin treatment was started in young, middle-145 
aged and old mice, concluded that, while rapamycin treatment extended lifespan and was able 146 
to rescue age-related decline in learning and memory and exploratory behaviour, many other 147 
traits were either unaffected or even worsened54. The reasons for the different findings are not 148 
clear. In addition to cancer, rapamycin is also protective in a wide range of mouse models of 149 
age-related disease, including metabolic diseases such as type 2 diabetes63; neurological 150 
diseases64,65 including Alzheimer’s disease66-69, Parkinson’s disease70, Huntington’s 151 
disease71,72, Leigh Syndrome73; lung diseases74, cardiovascular syndromes75 and many others76. 152 
 153 
The effects of rapamycin on ageing have also been investigated in two non-standard animal 154 
models. The Dog Aging Project77 conducted a randomized, double-blind, veterinary clinical 155 
trial to assess safety and effects of a 10-week, low-dose, non-immunosuppressive rapamycin 156 
treatment in healthy middle aged dogs78, which were recruited after an initial screen for factors 157 
including existing health conditions. Rapamycin was well tolerated, with no significant adverse 158 
effects, and led to an improvement in left ventricular systolic and diastolic function, similar to 159 
that previously reported in middle aged mice treated with rapamycin54,59,60. The improvement 160 
was particularly marked in the dogs with the lowest cardiac function before rapamycin 161 
treatment. Rapamycin will now be tested in dogs on a larger scale, including measures of 162 
cognitive and heart function, immunity and incidence of cancer77. Common marmosets 163 
(Callithrix jacchus) have been used to assess the effects of long-term (14 months) rapamycin 164 
treatment in a non-human primate that has similar age-related pathologies to those seen in 165 
humans79-81. There were no significant effects on body weight, activity, blood lipid 166 
concentrations or markers of glucose metabolism, and there were indications of tissue-specific 167 
up-regulation of components of the proteostasis network. 168 
 169 
The mTORC1 complex is a central cellular sensor and regulator with multiple inputs and 170 
downstream targets (FIG. 3a). Several molecular and cellular mechanisms may therefore 171 
contribute to the extension of lifespan by inhibition of mTORC182. Deletion of the mTORC1 172 
target S6K1 can extend the lifespan of female mice83, and inhibition of S6K1 kinase activity is 173 
required for rapamycin to extend Drosophila lifespan45, although in neither animal have the 174 
downstream mechanisms been elucidated. Increased macroautophagy (FIG. 3b) also plays a 175 
role, since blocking its increase in Drosophila treated with rapamycin prevents the extension 176 
of lifespan45. Rapamycin can also reverse the stem cell dysfunction that occurs during ageing 177 
in mouse hematopoietic48, tracheal and muscle stem cells84, as well as the intestine in mice85 178 
and Drosophila86. mTORC1 is also implicated in enhancing the survival and secretory 179 
phenotype of senescent cells, phenotypes that can be reversed by rapamycin87-90. 180 
 181 
The current clinical uses of rapamycin91,92 are limited by its toxic side-effects, which include 182 
hyperglycemia, hyperlipidemia, kidney toxicity, impaired wound healing, lowered blood 183 
platelet numbers and immunosuppression. As well as acutely inhibiting mTORC1, in some 184 
cells and tissues depending on FKBP12 levels93, prolonged treatment with rapamycin can also 185 
indirectly inhibit the mTORC2 complex, probably because rapamycin sequesters mTOR, 186 
limiting its availability to form mTORC2 complexes94,95. mTORC2 regulates cytoskeletal 187 
function, cell proliferation and survival, and importantly activates AKT, which controls the 188 
insulin signalling network. Inhibition of mTORC2 can thus impair glucose homeostasis in mice 189 
by blocking insulin-mediated suppression of hepatic gluconeogenesis94. Rapamycin is 190 
approved as an immunosuppressant for transplant surgery, because it can inhibit lymphocyte 191 
proliferation by blocking T cell activation96,97. Other studies indicate that rapamycin is more 192 
immunomodulatory in healthy individuals, with complex effects on specific lymphoid 193 
populations98-103. 194 
 195 
Both the animal studies and recent trials with humans indicate that pharmacological inhibition 196 
of mTORC1 can be geroprotective with much weaker and briefer inhibition than is used 197 
clinically, and with few if any side-effects. Immunosenescence [G] is a major problem in 198 
elderly humans, leading both to increased infections (particularly respiratory)104 and a reduced 199 
response to vaccination, including against influenza105. This age-related decline in immune 200 
function is partly attributable to a decreasing capacity for haematopoetic stem cells (HSCs) to 201 
generate naïve lymphocytes. Elderly mice show a similarly lowered response to vaccination 202 
against influenza, and a 6-week pre-treatment with rapamycin rejuvenated HSC function, 203 
increasing the level of naïve lymphocytes and boosting the response to immunization48. 204 
Inhibiting age-related immunosenescence in humans is a practical goal in a clinical trial, 205 
because any improvement can be assessed on a relatively short timescale. A double-blind 206 
clinical trial examined the effects of a 6-week treatment with the mTOR inhibitor RAD001, an 207 
analog of rapamycin, on the response to influenza vaccination in elderly volunteers106. After a 208 
6-week dosing regimen followed by a 2-week treatment-free interval, volunteers were given a 209 
seasonal influenza vaccination. RAD001 was generally well tolerated, particularly at lower 210 
doses. These treatments also met the primary endpoint of the study, which was a 1.2-fold 211 
increase in the geometric mean titres of antibodies to 2 out of 3 of the influenza strains present 212 
in the vaccine, an extent of increase previously associated with a decrease in influenza illness. 213 
The increase in titres was greatest in volunteers with low baseline influenza titres, suggesting 214 
that RAD001 was especially protective in individuals at greatest risk. Although no change in 215 
the percentage of naïve lymphocytes was detected, the pooled post-immunisation RAD001-216 
treated cohorts showed a lower percentage of PD-1-positive CD4 and CD8 T cells, which 217 
accumulate with age and have an impaired response to antigenic stimulation. A more recent 218 
study compared everolimus, another rapalog, with BEZ235, a dual PI3K/mTOR inhibitor, and 219 
a combination of the two (which proved most effective), finding that six weeks of dosing was 220 
sufficient to substantially reduce infections in the following year107. However, a Phase 3 221 
clinical trial failed to reach its primary endpoint108, and it will be important to resolve the 222 
reasons for the diverse findings of these clinical trials. 223 
 224 
Targeting the mTORC1 pathway currently carries the strongest preclinical and clinical 225 
evidence for its usefulness as a strategy to ameliorate ageing. Strategies to reduce risks 226 
associated with mTORC1 inhibition include improving dosing regimens for current rapalogs, 227 
combining rapalogs with kinase inhibitors and developing novel rapamycin variants with 228 
altered mTORC1/mTORC2 specificity. More human studies are also needed, but the balance 229 
of data suggests that reducing mTORC1 signalling may be a viable strategy to extend the 230 
human healthspan. 231 
 232 
[H2] Senolytics 233 
Cellular senescence is a permanent cell cycle arrest in normally proliferating cells in response 234 
to various stresses, including replicative exhaustion and DNA damage. Senescent cells become 235 
resistant to apoptosis and secrete an array of pro-inflammatory molecules and proteases, called 236 
the senescence associated secretory phenotype (SASP)109. Cellular senescence participates in 237 
tissue remodelling during development110 and in wound healing111, after which the senescent 238 
cells are normally removed by macrophages. It is also a potent anti-cancer mechanism because 239 
it occurs in response to stresses that make cells vulnerable to malignant transformation112. 240 
However, increased NF-kB signalling and expression of the pro-inflammatory cytokines IL-6 241 
and IL-8 are the most conserved and robust features of the SASP, and they can promote cell 242 
migration, growth and invasion, angiogenesis and, eventually, metastasis. Senescence can 243 
hence promote, as well as prevent, cancer113-115. During ageing in mice, senescent cells persist 244 
in multiple tissues, and can cause tissue damage because the SASP recruits inflammatory cells 245 
that remodel the extracellular matrix, trigger inappropriate cell death, induce fibrosis and 246 
inhibit stem cell function109,116,117. Senescent cells are involved in the aetiology of multiple 247 
human age-related diseases, including osteoporosis118,119, atherosclerosis120-122, hepatic 248 
steatosis123, fibrotic pulmonary disease124 and osteoarthritis114,115,125,126. Characterisation of the 249 
SASP proteomes of senescent cells has provided potential plasma markers for human ageing127. 250 
 251 
Genetic ablation of p16-expressing senescent cells in mouse can rescue features of ageing, 252 
including in kidney, heart and fat, with an associated preservation of functionality of glomeruli, 253 
cardio-protective KATP channels and adipocytes, respectively. Clearance also increased the 254 
median lifespan of the mice128,129. Ablation of senescent cells in obese mice improved 255 
metabolic function, reduced circulating inflammatory markers and reduced invasion of white 256 
adipose tissue (WAT) by macrophages130. Senescent cells are not abundant, even in aged 257 
tissues: a maximum of 15% has been reported, and genetic ablation only modestly reduced this 258 
number. Senescent cells have autocrine and paracrine effects, and can act at a distance on other 259 
cell types131, which may explain why a mild reduction in their number can be beneficial. 260 
 261 
Chemical elimination of senescent cells by senolytics (FIG. 4), or disruption of the SASP by 262 
senostatics [G], are potentially attractive strategies for combating a broad range of age-related 263 
conditions. Inhibition of the SASP would require continuous treatment, because the senescent 264 
cells persist. The composition of the SASP varies, depending upon both the original cell type 265 
and the nature of the stress that induced senescence, so specific senescent cell subtypes could 266 
potentially be targeted. Because senolysis eliminates senescent cells, a brief treatment could be 267 
used, which has the advantage of leaving cell senescence during wound healing unimpaired. 268 
Senescent cells express diverse markers and use a variety of mechanisms to resist apoptosis, 269 
providing a further basis for the specificity of senolytics. 270 
 271 
Senescent cells become resistant to apoptosis. Pro-survival pathways in senescent cells include 272 
those mediated by members of the BCL2 family, PI3K/AKT, p53/FOXO4, HSP90 and HIF1a. 273 
Pharmacological targeting of BCL2 family members can eliminate senescent cells induced by 274 
radiation in mouse lungs and in aged mice132 (FIG. 4a), since levels of these proteins are 275 
elevated in senescent cells to inhibit mitochondrial activation of apopotosis, but induce 276 
thrombocytopenia as a side-effect. However, combination of BCL2 inhibition, by the flavonoid 277 
quercetin, with dasatinib, which inhibits multiple tyrosine kinases, reduced the number of 278 
senescent cells in WAT and the liver, increased the cardiac ejection fraction and vascular 279 
endothelial function in old mice, and reduced the senescent cell burden in several tissues, as 280 
well as increasing healthspan in progeroid mice132. Intermittent administration of the two drugs 281 
improved vasomotor function in aged mice122, which led to improved cardiovascular function 282 
and exercise endurance, and reduced osteoporosis and frailty. A combination of dasatinib and 283 
quercetin, administered orally to >24 month mice, led to a 36% increase in the remaining 284 
lifespan, and did not cause prolonged late-life morbidity133. Combination treatment with 285 
dasatinib and quercetin also ameliorated uterine ageing in mice134. Because dasatinib and 286 
quercetin affect the activity of multiple proteins, it will be important to determine their 287 
associated in vivo effects on non-senescent cells, as well as their senolytic activity. 288 
 289 
Expression of the transcription factor FOXO4 increases during radiation-induced senescence 290 
in fibroblasts, and preventing this increase leads to apoptosis. Perturbing the interaction of 291 
FOXO4 with p53 with a FOXO4 peptide caused nuclear exclusion of p53 and apoptosis of 292 
senescent cells135(FIG. 4b). Doxorubicin induces cellular senescence in mouse and human 293 
liver, together with increased expression of FOXO4, and preventing the increase reduced 294 
doxorubicin-induced senescence and liver toxicity. Preventing the interaction between p53 and 295 
FOXO4 also reduced cellular senescence and several phenotypes of ageing in a mouse model 296 
of accelerated ageing, and reduced frailty and loss of renal function in naturally aged mice135, 297 
potentially providing another target for senolysis. 298 
 299 
A chemical screen in mouse embryonic fibroblasts with reduced DNA repair capacity 300 
identified that two HSP90 inhibitors induce apoptosis specifically in senescent cells. Treatment 301 
of Ercc1-/∆ mice, a mouse model of a human progeroid syndrome, with the HSP90 inhibitor 302 
17-DMAG extended healthspan, delayed the onset of several age-related symptoms and 303 
reduced p16INK4a expression136 (FIG. 4c). HSP90 plays roles in protein folding, stabilisation 304 
and proteasomal degradation, and in cellular stress responses. It has been targeted in cancer, 305 
although so far no licensed drugs targeting HSP90 exist. HSP90 has multiple isoforms, and 306 
these are targeted by different HSP90 inhibitors, potentially allowing specific targeting of 307 
senescent cells137. 308 
 309 
In addition to quercetin, another natural product, fisetin, has been shown to have senolytic 310 
properties. A recent report found that administration of fisetin to mice late in life was sufficient 311 
to reduce age-related pathology and extend both median and maximum lifespan12. This 312 
approach offers an attractive alternative to other senolytic compounds that may have greater 313 
toxicity. However, and as with other natural products, fisetin has a number of activities138, 314 
making it hard to attribute its beneficial effects to ablation of senescent cells. 315 
 316 
More recently, two studies139,140 report cardiac glycosides as powerful and specific senolytics. 317 
These compounds, including digoxin, digitoxin and ouabain, target the Na+/K+ ATPase pump, 318 
resulting in disruption of the cellular electrochemical gradient and hence cellular acidification 319 
(FIG. 4d). Senescent cells already have an acidic pH, which may explain their selective 320 
vulnerability to apoptosis when treated by cardiac glycosides. The compounds selectively 321 
killed cells in which diverse inducers had led to senescence and, in combination with other 322 
chemotherapeutics, they also inhibited tumour xenograft growth, killed senescent pre-323 
neoplastic cells, and attenuated some features of ageing in mice. Cardiac glycosides are used 324 
to treat congestive heart failure and cardiac arrhythmias, and these observed senolytic effects 325 
were achieved at clinical doses. These are promising findings that warrant further work with 326 
these compounds. 327 
 328 
Clinical trials are already underway for the treatment of osteoarthritis with the senolytic 329 
UBX0101141 and of idiopathic pulmonary fibrosis with dasatinib and quercetin142 (FIG. 4a). 330 
Targeting senescent cells in ageing is also a promising prospect, but there are important 331 
outstanding questions143,144. So far, most classified senolytics may also affect non-senescent 332 
cells, and any such effects need to be evaluated. Timing of senolytic treatment may also be 333 
important, because it could result in exhaustion of stem cells. Finally, failure to clear apoptotic, 334 
senescent cells could also be problematic. Therefore, precise targeting of senolytics to specific 335 
senescent cell types may help circumvent these potential hurdles. 336 
 337 
[H2] Metformin 338 
Metformin is a biguanide drug widely prescribed for type 2 diabetes145-147. In 2013, it was 339 
estimated that 83.6% of individuals in the UK with type 2 diabetes were prescribed metformin, 340 
and in 2012148 there were 61.6 million prescriptions for metformin in the USA149,150. Metformin 341 
is derived from a compound isolated from French lilac (goat's rue, galega officinalis), which 342 
was used for centuries as a herbal remedy for treatment of frequent urination (a symptom of 343 
diabetes151). FDA approval came in 1994145. Metformin reduces diabetic hyperglycemia by 344 
suppressing hepatic gluconeogenesis, inducing glycolysis and increasing insulin sensitivity152; 345 
it also reduces lipolysis, and lowers levels of circulating free fatty acids. 346 
 347 
Preclinical studies of metformin suggest a role for the drug in mitigating ageing. Metformin 348 
robustly increases lifespan in C. elegans by up to 36%155, and this effect has been attributed to 349 
AMP kinase (AMPK) activation153, mitohormesis154, the lysosomal pathway and metabolic 350 
alterations of the microbiome155. Recent studies suggest that alterations of the microbiome may 351 
also mediate some of the anti-diabetic effects of metformin in humans156. In Drosophila, 352 
metformin did not increase lifespan, though it did activate AMPK and reduce lipid stores157. 353 
Initial studies showed effects on ageing in mice158, but these studies were performed in short-354 
lived mouse models that, in some cases, are prone to developing cancer. Two recent studies 355 
have been performed in the relatively long-lived C57/Bl6 and genetically outbred mice159,160 356 
in which slightly increased longevity reached statistical significance in some contexts159. 357 
Metformin did not increase lifespan in the outbred mice in the ITP (BOX 4). The more modest 358 
effects seen in long-lived mouse strains is a cause for concern, although another possibility is 359 
that metformin may be more effective in more stressful situations that shorten lifespan. 360 
 361 
Metformin interacts with several known longevity pathways. Its effects resemble those of 362 
dietary restriction [G] (DR), including increased insulin sensitivity, and metformin-treated 363 
mice have DR-like mRNA profiles160,161. Mechanistically, the strongest evidence is that 364 
metformin inhibits complex I of the electron transport chain, leading to reduced ATP levels 365 
and activation of AMPK; however, many but not all phenotypes associated with metformin 366 
administration are AMPK-dependent162,163. Consistent with observations in C. elegans, 367 
metformin also alters mouse and human microbiomes in a manner that appears anti-368 
inflammatory164-167. More directly, metformin has been reported to repress TNFa-dependent 369 
IkB degradation and consequent expression of inflammatory cytokines, in a manner 370 
independent of AMPK and mitochondrial action168-172. This property may underlie its ability 371 
to suppress the SASP in senescent cells173. Metformin also binds the alarmin HMGB1 and 372 
inhibits its proinflammatory activity174. More recently, the H3K27me3 demethylase 373 
KDM6A/UTX has been proposed as a direct target of metformin, suggesting a role in 374 
chromatin modification175. 375 
 376 
Retrospective, epidemiological analyses of data from patients prescribed metformin have 377 
concluded that its use is associated with reductions in: CVD incidence and mortality176-179; 378 
cancer rates179-187; overall mortality188; and depression and frailty-related diseases179. Meta-379 
analyses of metformin in age-related conditions are also encouraging (but not always positive), 380 
with a range of studies showing protection from cancer, CVD, chronic kidney and liver disease, 381 
and neurodegeneration. One study detected an 18% increase in median all-cause survival in 382 
metformin-treated individuals with diabetes relative to the rest of the population, despite higher 383 
levels of morbidity in the former189, a finding replicated in a more recent study190 and in a 384 
systematic review of clinical studies191, but not in another large meta-analysis192. However, 385 
these studies were all conducted in groups with type 2 diabetes, and metformin could have been 386 
beneficial for these other conditions because it mitigates the effects of diabetes rather than of 387 
ageing. It is thus not clear if metformin would have benefits in non-diabetic individuals. 388 
Although they are intriguing, these clinical epidemiological studies have other limitations from 389 
the standpoint of assessing the use of metformin in ageing: they assess patients with diabetes, 390 
who have enhanced mortality rates compared to the unaffected population; some studies 391 
compare metformin to other diabetes drugs, which could have adverse effects; and metformin 392 
users have had contact with a clinician, and hence may on average have greater health-seeking 393 
behaviours than control populations. 394 
 395 
The Targeting Aging with Metformin (TAME) initiative was proposed to study effects of 396 
metformin on 3,000 non-diabetic people, aged 65-79, at many centres in the U.S. with an 397 
estimated cost of US$50 million193,194. The effects of metformin are to be examined on multiple 398 
markers of age-related health, including CVD, cancer, dementia and mortality, under the 399 
premise that a drug that extends healthspan would prevent onset of many distinct age-related 400 
conditions195. A small, short-term intervention in healthy adults has also been performed, and 401 
showed that metformin triggers both metabolic and non-metabolic pathways linked to ageing 402 
in non-diabetic individuals of average age 70196. Metformin has an excellent safety profile, and 403 
the TAME initiative will serve as a benchmark in the development of metformin (and possibly 404 
other geroprotectors) for use in humans to offset ageing. However, an experimental study has 405 
indicated that metformin can blunt the increases in whole-body insulin sensitivity and skeletal 406 
muscle mitochondrial respiration in response to aerobic exercise training in older adults, with 407 
marked individual differences in the responses197. It will therefore be important to understand 408 
how metformin affects muscle physiology and function with and without exercise, and how 409 
much individual variability exists in responses, and to find predictive biomarkers for positive 410 
responders. 411 
 412 
[H2] Acarbose 413 
Metabolic dysfunction is commonly observed in human ageing, and type 2 diabetes is a risk 414 
factor for several other age-related conditions, including CVD, kidney disease, cancer and 415 
dementia198. Maintenance of glycemic control during ageing could thus induce multiple health 416 
benefits. Acarbose is a bacterial product that inhibits α-glucosidases in the intestine, thus 417 
slowing the breakdown of starch and disaccharides to glucose. It is used clinically to prevent 418 
post-prandial hyperglycemia199, and generally causes weight loss and improved glycemic 419 
control198. Acarbose can rescue age-related glucose intolerance in rats200 and it has been 420 
considered as a potential mimetic of DR201. 421 
 422 
In the ITP (BOX 4), acarbose increased median lifespan in male mice by 22%, with only a 423 
small effect in females (5%), but maximum lifespan was significantly increased in both sexes 424 
(females 9%, males 11%). Body weight was reduced (more so in females than in males) fasting 425 
blood glucose levels and IGF1 levels in plasma were lower in both sexes, and fasting insulin 426 
levels were lower only in males. Acarbose increased the healthspan in mice, with reductions in 427 
lung tumours in males, liver degeneration in both sexes, glomerulosclerosis in females, and 428 
blood glucose response to refeeding in males, and improved rotarod performance in ageing 429 
females202. In male mice, acarbose also reduced post-mortem liver degeneration, lipidosis201 430 
and hypothalamic inflammation203, and abolished male-specific insulin insensitivity and 431 
glucose intolerance204, all of which potentially contributed to the greater effect of the drug on 432 
male lifespan, which, interestingly, was abolished by castration204. Acarbose-treated mice 433 
showed alterations in the composition and fermentation products of their microbiome and in 434 
the composition of the short chain fatty acids in the gut, although these effects differed between 435 
the 3 ITP test sites205. It is likely that acarbose and DR increase lifespan by partly different 436 
mechanisms, because DR reduced levels of circulating FGF21 and increased activity levels, 437 
whereas acarbose had opposite effects on these phenotypes201. In summary, although acarbose 438 
has some undesirable, although not dangerous, digestive side effects206, there are ample reasons 439 
to evaluate this small molecule in the clinical as it may be among the most efficacious 440 
geroprotectors identified to date. 441 
 442 
[H2] Spermidine  443 
Spermidine is a naturally occurring polyamine that plays key roles in control of gene 444 
expression, apoptosis and autophagy, and is essential for cell growth and proliferation207. 445 
Levels of spermidine decline during ageing in both model organisms and several human 446 
organs208,209. Spermidine is classified as a geroprotector because supplementation of 447 
spermidine in the diet can extend lifespan in yeast, C. elegans, Drosophila and mice, and 448 
addition to the culture medium can increase survival of human immune cells209-211. In 449 
Drosophila, increased production of spermidine contributes to extension of lifespan by 450 
reducing insulin/IGF signalling212. Additionally, a prospective, population-based study in 451 
humans found an association between high levels of spermidine in the diet and reduced all-452 
cause mortality213. 453 
 454 
Spermidine may exert its geroprotective effects by more than one mechanism: studies have 455 
implicated increased autophagy and, in mammals, protection of cardiac and immune function. 456 
Feeding spermidine increases the serum levels of free thiols in old mice to levels seen in youth, 457 
potentially indicative of reduced oxidative stress209. In yeast and mammalian cells, spermidine 458 
supplementation decreases histone H3 acetylation209, with possible functional consequences 459 
for gene expression. Spermidine inhibits the acetyl transferase activity of EP300, which in turn 460 
inhibits autophagy, as EP300 normally acetylates lysine residues in autophagy-related 461 
proteins214,215. Accordingly, in yeast, C. elegans, Drosophila and in human cells, spermidine 462 
increases markers of autophagy, and mutants blocking the increase in autophagy prevent the 463 
increase in survival in response to spermidine, implying a causal connection209. 464 
 465 
In mice, the increased lifespan from supplemented dietary spermidine is associated with a delay 466 
in the age-related decline in cardiovascular function210,211. Increased dietary spermidine 467 
upregulates autophagy, mitophagy and mitochondrial biogenesis and function in the heart216, 468 
and it also improves the mechanical properties of cardiomyocytes in vivo, benefits that are lost 469 
if the increase in autophagy is blocked. Furthermore, high levels of dietary spermidine in 470 
humans correlate with reduced blood pressure and a lower incidence of CVD210. Spermidine 471 
can also enhance immunity. Autophagy declines specifically in B and T cells in aged mice, and 472 
a 6-week spermidine treatment attenuated this decline and improved B cell function. 473 
Spermidine promotes the hypusination of the translation factor eIF5A, which is required for 474 
synthesis of the autophagy transcription factor TFEB, so supplementation with spermidine 475 
restored this pathway and reversed the senescence of old human B cells217. Because spermidine 476 
can reverse the reduction of polyamine synthesis and autophagy observed in aged and 477 
osteoarthritic cartilage, it is also a promising candidate for prevention of osteoarthritis218. 478 
Finally, spermidine can also improve stem cell function in muscle of old mice219, and is 479 
neuroprotective in Drosophila220 and mice221,222.  480 
 481 
Clinical trials with spermidine could thus be considered 223, although some caution may be 482 
warranted given that targeting polyamine metabolism is being considered for both 483 
chemotherapy and chemoprevention in cancer224. As increased autophagy is a recurring theme 484 
for geroprotectors, it will be important to understand the downstream mechanisms of protection 485 
and the most effective means of inducing them. 486 
 487 
[H2] NAD+ enhancers 488 
NAD+ is a coenzyme that catalyzes a wide range of cellular metabolic functions through 489 
cellular redox reactions, in which it becomes converted to NADH. These reactions are scattered 490 
throughout the glycolytic pathway, the tricarboxylic acid cycle and β-fatty acid oxidation, 491 
among other cellular functions. However, NAD+ also acts as a substrate for sirtuins, Poly-492 
ADP-ribose polymerases and CD38, reactions through which it is consumed225-227. Levels of 493 
the compound decrease with ageing in mammals228-230, contributing to a reduction in activity 494 
of sirtuins. Strategies to supplement NAD+ levels lead to increased healthspan in mice231,232; 495 
however, the myriad cellular roles of the small molecule have made it difficult to link 496 
phenotypes to its specific biochemical actions. 497 
 498 
NAD+ is not taken up by cells, making direct supplementation infeasible. It is possible to 499 
exploit NAD+ synthesis pathways through addition of precursors to increase NAD+ levels in 500 
vivo: the two most commonly tested in vivo are nicotinamide riboside (NR) and nicotinamide 501 
mononucleotide (NMN). Both have been tested in invertebrate and murine ageing studies225-502 
227. NR increases yeast replicative lifespan233, and both NR and NMN increase worm 503 
lifespan234. In mice, NR elicits a wide range of beneficial effects, including a modest lifespan 504 
extension231. NMN administration in mice also leads to a range of beneficial phenotypes during 505 
ageing232,235, including an improvement in oocyte quality236, although altered lifespan has not 506 
been reported. Both NR and NMN are also reported to be protective in a range of age-associated 507 
disease models225-227. 508 
 509 
Given that NR and NMN are natural products, both are being tested in humans and there is 510 
extensive debate over which of the two molecules is likely to be most efficacious. Differences 511 
in bioavailability and stability have been reported. NMN is being tested in clinical studies, but 512 
findings have not yet been published. Several studies have been completed with NR, although 513 
trial sizes are generally quite small. Common conclusions of the trials are that NR is 514 
bioavailable237, increases NAD+ levels238,239, and can be administered safely240. One recent 515 
study showed that NR administration in aged men for three weeks was sufficient to reduce 516 
inflammatory cytokine levels241. In another study, however, no improvement in metabolism 517 
was detectable in obese, insulin-resistant men242. Further work is needed to determine whether 518 
NR or NMN have advantageous properties in humans. Given that NAD+ precursors are natural 519 
products that are already on the market, it will be critical to better define their effects on 520 
healthspan. 521 
 522 
[H2] Lithium  523 
By the middle of the 19th century, lithium carbonate was used as a medical treatment for a range 524 
of disorders, including cancer, whereas now it is mainly used to treat bipolar disorder. Lithium 525 
induces a dose-dependent extension of lifespan in fission yeast266, C. elegans267-269 and 526 
Drosophila270, with higher doses highly toxic to survival. In C. elegans and Drosophila, 527 
locomotor performance during ageing is also maintained by lithium treatment269,270. 528 
Experimental effects of the drug on mammalian lifespan have not yet been reported. In humans, 529 
lithium treatment has been associated with longer leukocyte telomeres271, and comparatively 530 
high natural levels in the drinking water in parts of Japan have also been linked to lower suicide 531 
rates272,273 and reduced all-cause mortality268. Mesenchymal stem cells from ageing humans 532 
show impaired myogenic differentiation, a defect associated with impaired Wnt/β-catenin 533 
signalling, which can be rescued by lithium274. Lithium is neuroprotective275,276 and can 534 
ameliorate pathology in several animal models of disease, including Alzheimer’s disease, 535 
Huntington's disease and stroke277-279.  536 
 537 
Lithium has multiple targets, and its mode of action as a drug in humans is incompletely 538 
understood. It can induce autophagy in mammalian cells in culture, by inhibition of inositol 539 
monophosphatase280. Consistently, extension of lifespan in C. elegans is accompanied by 540 
increased autophagy, as well as increased mitochondrial DNA copy number and enhanced 541 
energetics269. In Drosophila, lifespan-extension is mediated by suppression of GSK3 and hence 542 
activation of the cap-n-collar transcription factor CncC, the fly orthologue of mammalian 543 
NRF2, accompanied by a hormetic response to lithium itself and to xenobiotics270.  544 
 545 
There is currently no evidence for geroprotective effects of lithium in mammals, and its narrow 546 
therapeutic range is a problem for widespread, long-term use. If activation of autophagy 547 
mediates its benefits, other auotphagy inducers could be used or lithium could be combined 548 
with, for instance, mTORC1 inhibitors, to allow lower doses with fewer side-effects to be 549 
used281. Clearer identification of the therapeutic targets of lithium, especially in mammals, may 550 
also yield more specific drugs.  551 
 552 
[H1] Tier 2 553 
[H2] NSAIDs  554 
Non-steroidal anti-inflammatory drugs (NSAIDs) are used to treat mild-to-moderate pain and, 555 
at higher doses, to decrease inflammation. The primary target for this class of drugs, which 556 
include aspirin and ibuprofen, are cyclooxygenases (COX1 and COX2)243, although NSAIDs 557 
also have antithrombotic and anti-oxidant activities that probably occur through at least 558 
partially different mechanisms244. Aspirin (acetylsalicylic acid) is reported to extend lifespan 559 
in C. elegans245, Drosophila246,247 and male mice248; the sex-skewed effects in mice are possibly 560 
attributable to a higher ratio, in males, of aspirin to its metabolite, salicylic acid. However, this 561 
lifespan extension was not repeatable by the ITP (BOX 4). In C. elegans, lifespan extension 562 
by aspirin requires DAF16/FOXO, AMPK, and LKB1, but not SIR-2.1, and aspirin does not 563 
further extend the lifespan of DR animals245. In mammals, both COX-dependent and 564 
independent effects of aspirin, which include activation of AMPK and consequent inhibition 565 
of mTORC1249, together with inhibition of IKKβ250 and Wnt/β-catenin 251, mean that multiple 566 
mechanisms could contribute to altered ageing244. 567 
 568 
Interestingly, ibuprofen has been reported to extend lifespan in yeast, worms and flies, through 569 
a mechanism (at least in yeast) that involves degradation of the tryptophan transporter, which 570 
reduces intracellular amino acid pools and consequently inhibits mTOR252. A third NSAID, 571 
celecoxib, has also been reported to extend C. elegans lifespan through an insulin–IGF-572 
dependent mechanism253. Ibuprofen, aspirin, and celecoxib have not been directly compared to 573 
determine if they function through common mechanisms for lifespan extension. Another 574 
NSAID, a nitrosylated variant of flurbiprofen, failed to alter mouse lifespan248. 575 
 576 
Epidemiological evidence links NSAIDs to protection from a range of chronic diseases of 577 
ageing. For instance, long-term aspirin users are reported to experience a 33% reduction in 578 
colorectal cancer incidence and mortality254,255, through mechanisms that remain unclear. In a 579 
panel of tumour cell lines, aspirin strongly suppressed cell size and cell growth, with lowered 580 
phosphorylation of the mTORC1 targets p70S6K and S6, through both AMPK-dependent and 581 
AMPK-independent mechanisms256. Aspirin may also reduce metastatic spread, possibly 582 
through a platelet-mediated mechanism257,258. Multiple epidemiological studies of aspirin in 583 
primary prevention of stroke, myocardial infarction/coronary events and cardiovascular death 584 
in those without a history of CVD have concluded that aspirin modestly reduces nonfatal 585 
myocardial infarction/coronary events and major CVD events, and at daily doses of less than 586 
100 mg reduces the incidence of stroke, with both effects increasing with age259. However, 587 
aspirin also increases major gastrointestinal bleeding risk, thus complicating conclusions about 588 
net benefit259. Similarly, ibuprofen has been reported to reduce the risk of both Alzheimer’s 589 
disease and Parkinson's disease48,260, although these findings remain controversial261. 590 
 591 
Unfortunately, clinical trials with aspirin in primary prevention have largely failed to confirm 592 
the promising epidemiological findings. Trials with healthy elders found no evidence of 593 
protection against cardiovascular events and there was an observed increase in the incidence 594 
of gastrointestinal bleeds242,262. Although there was some protection against cardiovascular 595 
events in adults with type 2 diabetes, this protection was counterbalanced by major bleeding 596 
events263. One trial found no effect of aspirin use on disability-free survival264 and a significant 597 
increase in all-cause mortality, primarily attributable to an increased incidence of cancer265. 598 
Although NSAIDs have some characteristics of geroprotective drugs, the current clinical 599 
evidence raises significant doubts regarding ageing studies in humans. 600 
 601 
[H2] Reverse Transcriptase Inhibitors  602 
The human genome is littered with a large number of repeated elements, among which long 603 
interspersed nuclear elements (LINEs) are the most prevalent, comprising roughly 20% of the 604 
mouse and human genomes282,283. A subset of the 6 kilobase LINEs are fully functional 605 
retrotransposable elements, relying on an encoded reverse transcriptase to excise from the 606 
genome and reinsert in other locations, and are hence a source of genome instability284-286. 607 
LINE1 activation has been linked to age-related diseases286-288 and is also prevalent in a 608 
progeroid model, Sirt6-/- mice289,290. Consistently, SIRT6 enzyme activity is one of several 609 
mechanisms by which cells suppress LINE1 activation289. 610 
 611 
A number of nucleoside reverse transcriptase inhibitors (NRTIs) have been generated and used 612 
in the clinic to inhibit HIV reverse transcriptase and, fortuitously, some of these also impair 613 
the reverse transcriptase activity associated with ORF2 of LINE1291,292. Two recent studies 614 
reported that NRTIs can ameliorate pathologies linked to ageing in mice293,294. In both studies, 615 
LINE1 elements, expressed specifically in late-stage senescent cells, were not restricted to the 616 
nucleus and accumulated in the cytoplasm and activated the IFN-1 interferon response, which 617 
may underlie induction of the SASP and some of the chronic inflammation associated with 618 
ageing. In one report, the NRTIs lamivudine and stavudine were found to reduce DNA damage, 619 
suppress in vivo pathology and extend the lifespan of Sirt6-/- mice293. This study also found 620 
activation of LINE1 elements with ageing, as previously reported. A contemporaneous report 621 
focused on cell senescence, and reported that lamivudine reduced the SASP and inflammation 622 
in aged mice294. It is yet to be demonstrated that NRTI treatment results in enhanced mouse 623 
longevity, although it is reported to reduce DNA methylation age293, an emerging biomarker 624 
of ageing. These findings make NRTIs interesting new geroprotector candidates. However, any 625 
strategy to employ NRTIs as a means to enhance human healthspan will have to account for 626 
their associated side effects in the clinic295. 627 
 628 
[H2] Systemic Circulating Factors 629 
Dysregulated intercellular communication is a hallmark of ageing, and is characterised inter 630 
alia by age-related, sterile inflammation, often known as ‘inflammaging’296,297, and a 631 
deteriorating systemic environment that impairs the function of multiple tissues298,299. 632 
Therefore, altering the concentration of select blood metabolites to improve health during 633 
ageing is receiving increased attention. 634 
 635 
Heterochronic parabiosis, in which the circulatory systems of mice of different ages are 636 
shared300, has shown that stem cell regenerative capacity of muscle301,302, liver301, spinal cord303 637 
and brain304 of old mice is improved by a young systemic environment. Young blood can also 638 
reverse these age-related effects: structural deterioration and molecular changes in mouse 639 
kidney305; decline in β-cell replication306; and decline in bone repair and regenerative 640 
capacity307. In an extension of the parabiosis concept, human umbilical cord plasma, 641 
administered to immunocompromised mice, induced expression of genes in the hippocampus 642 
that suggested increased long-term potentiation and memory, and also increased long-term 643 
potentiation in hippocampal brain slices and improved cognitive function in old mice308. 644 
 645 
Progress has been made in identifying the mechanisms and molecules that impair the ageing 646 
systemic environment. For instance, exposure to young blood ameliorates declines in cognitive 647 
function, and of dendritic spine density and synaptic plasticity in hippocampal neurons of 648 
ageing mice, mediated in part by activation of cyclic AMP response element-binding protein 649 
(CREB)309. Levels of β2-microglobulin, a component of major histocompatibility complex 650 
class 1 (MHC I) molecules, increase during ageing and negatively regulate cognitive function 651 
and regenerative capacity in the hippocampus of ageing mice310. In addition to these identified 652 
components, methylcytosine dioxygenase TET2 catalyses the production of 5-653 
hydroxymethylcytosine (5hmC), and the levels of both TET2 and 5hmC decline in mouse 654 
hippocampus during ageing. TET2 expression levels are restored in the hippocampus of old 655 
heterochronic parabionts, and inhibition of TET2 expression in young mice impairs 656 
neurogenesis and cognitive function, whereas TET2 overexpression restores these biological 657 
functions and 5hmC levels in old mice311. 658 
 659 
The growth differentiation factor 11 (GDF11) levels in mouse blood have been reported to 660 
decline with age. Age-related cardiac hypertrophy in old mice is ameliorated by exposure to 661 
young blood, and a proteomic screen identified GDF11 as a mediating factor312. Furthermore, 662 
supplementation of GDF11 by heterochronic parabiosis or direct delivery restored stem cell 663 
function and structure, increased strength and endurance exercise capacity in ageing mice313, 664 
and increased cerebral blood flow, neural stem cell proliferation and olfactory neurogenesis 665 
and function314. Other studies have reported that GDF11 levels in rat and human sera instead 666 
increase with age, and that administration of GDF11 inhibits muscle regeneration and stem cell 667 
division in mice315. To this end, the specificity of detection of GDF11 may have played a role 668 
in these discrepant findings316. 669 
 670 
In addition to the components described above, young blood reverses the declines in fracture 671 
repair and osteoblastic differentiation capacity of old mice by modulating signalling through 672 
β-catenin307. Combined proteomic analysis of human umbilical cord plasma and of changes in 673 
mouse plasma during ageing produced a list of candidate proteins for rejuvenation of the ageing 674 
mouse hippocampus. One of these, metalloproteinase inhibitor 2 (TIMP2), improved learning 675 
and memory in aged mice when directly administered, whereas depletion of TIMP2 in cord 676 
plasma abolished its rejuvenating effects308. The protein vascular cell adhesion protein 1 677 
(VCAM1), a member of the immunoglobulin superfamily, increases in expression in mouse 678 
and human plasma during ageing. It is induced in endothelial cells in response to inflammation 679 
and facilitates leucocyte tethering. Anti-VCAM1 antibody administration, or genetic ablation 680 
of VCAM1 specifically in brain endothelial cells, counteracted the adverse effects of plasma 681 
from aged mice on microglial activation, neural progenitor cell activity and cognition in young 682 
mice317.  683 
 684 
Identification of blood factors that improve the youthful, or impair the ageing, systemic 685 
environment is opening translational opportunities. A preclinical study showed that parabiosis 686 
with a young mouse or direct administration of plasma from young mice could ameliorate 687 
molecular defects in hippocampus and impaired working memory in a mouse model of 688 
Alzheimer's disease318, and a recent, randomised clinical trial concluded that administration of 689 
young plasma to patients with mild to moderate Alzheimer's disease-associated dementia was 690 
safe, tolerable and feasible319. Given the ready accessibility of the human circulatory system, 691 
modulation of its molecular composition is an approach of considerable promise. 692 
 693 
[H2] The microbiome 694 
The vast assemblage of microorganisms associated with animals is increasingly recognised to 695 
play a significant biological role. Both the population size and composition of the gut 696 
microbiome change with age in C. elegans, Drosophila, mice and humans320-323. A broad 697 
spectrum improvement in health in diverse organisms is induced with DR. In mice, transfer of 698 
gut microbiome from subjects following DR to a sterile recipient resulted in reduced weight 699 
gain and increased glucose tolerance, insulin sensitivity, and glucose uptake into WAT, which 700 
also resulted in WAT browning 324. These results suggest that some of the health benefits of 701 
DR may be caused by changes in the composition of the microbiome. Transfers of gut 702 
microbiome of young turquoise killifish to older recipients delayed the age-related changes in 703 
microbiome composition and improved swimming performance and extended the lifespan of 704 
older recipients325. It is not yet understood how these health improvements from microbiome 705 
transfer are mediated, but they likely involve changes to the overall composition of metabolites 706 
produced either by or in response to microbiome constituents . Therefore, it will be important 707 
to identify these metabolite changes to understand the downstream biological effects and 708 
determine if this can offer a more standardised intervention to improve health during ageing. 709 
 710 
[H2] Glucosamine 711 
Glucosamine is an essential amino-monosaccharide component of glycoproteins, 712 
proteoglycans and glycosoaminoglycans. It is widely used as a supplement for individuals with 713 
osteoarthritis, but recent literature suggests that it has potential benefits for a wide range of 714 
chronic diseases, including cancer, skin disorders, and CVD326. Glucosamine extends lifespan 715 
in C. elegans and confers modest lifespan extension when administered to old mice327. In 716 
worms, glucosamine was found to extend lifespan in a manner independent of the hexosamine 717 
pathway, through a mechanism that may mimic a low carbohydrate diet. Consistent with this 718 
hypothesis, AMPK was activated and mitochondrial biogenesis was enhanced. Interestingly, 719 
glucosamine stimulated reactive oxygen species (ROS) production, a finding consistent with 720 
reports that under some circumstances increased ROS production in worms can enhance 721 
longevity328 and trigger AMPK activation329. Studies in mice correlated with these findings, as 722 
mitochondrial biogenesis was also found to be enhanced.  723 
 724 
Glucosamine has a wide range of other effects in mammals that could be linked to ageing326, 725 
including acting as an anti-inflammatory agent, inhibiting mTOR and stimulating autophagy, 726 
paradoxically acting as an anti-oxidant and, through its conversion to uridine diphosphate N-727 
acetylglucosamine (UDP-GlcNAc), as a substrate for O-GlcNAc modification of proteins, 728 
which itself is linked to many protective effects against chronic disease330. Glucosamine and 729 
related molecules need to be evaluated further to determine the mechanisms by which they act 730 
and to validate them as geroprotective agents. 731 
[H2] Glycine  732 
A recent study by the ITP (BOX 4) showed that glycine supplementation leads to both median 733 
and maximum lifespan extension in mice of both sexes331. This finding supports an earlier 734 
report of enhanced longevity in rats332 and recent studies in C. elegans333,334. In both of the 735 
rodent studies, glycine administration was also associated with weight loss, but only in females. 736 
Glycine has also been reported to have anti-cancer and anti-inflammatory effects in rodents335-737 
337. In limited human clinical studies, glycine supplementation may be protective in the context 738 
of metabolic diseases336,338, although larger studies are needed. 739 
 740 
In a number of nutritional studies, reduced amino acids are associated with longer lifespan, 741 
making the results with glycine potentially paradoxical339-342. However, glycine has a unique 742 
property in that it is an acceptor of methyl groups in the catabolism of methionine by glycine 743 
N-methyl transferase, and thus serves an important role in hepatic methionine clearance338. 744 
Methionine restriction is known to enhance longevity in several model organisms of ageing343, 745 
but this restriction is difficult to implement practically, so glycine supplementation could be a 746 
preferable alternative. 747 
 748 
The mechanisms by which glycine extends lifespan may, however, be more complex, because 749 
glycine supplementation in C. elegans may influence one carbon metabolism and the 750 
production of S-adenosyl methionine, resulting in transcriptional changes through epigenetic 751 
mechanisms333. Serine, which also acts in one carbon metabolism, was also found to extend 752 
lifespan through a similar mechanism333. C. elegans may have key differences from mammals 753 
regarding amino acid supplementation, as a prior report found that a supplementation of a wide 754 
range of amino acids led to lifespan extension334. In summary, there is significant promise for 755 
glycine in modulating ageing, so efforts to understand its modes of action are essential. 756 
 757 
[H2] 17- α estradiol 758 
17- α estradiol (17α-E2) is a nonfeminizing estrogen with reduced affinity for the estrogen 759 
receptor. The ITP demonstrated that 17α-E2 extends lifespan preferentially in male mice201, 760 
and a later study replicated this sex difference even at higher doses344 (BOX 4). The male-761 
specific benefits extend to metabolic phenotypes, including increased insulin sensitivity and 762 
glucose tolerance 204, and require gonadal hormones, as castrated males were refractory to 17α-763 
E2, whereas ovariectomized females showed a metabolic response. The metabolic benefits 764 
were linked to increased hepatic mTORC2 and AKT signalling, accompanied by FOXO1A 765 
phosphorylation. In young mice, 17α-E2 reduced overall body mass and increased the lean-to-766 
fat mass ratio345. In older mice, however, the hormone preserved body weight and muscle 767 
strength in males346. 768 
 769 
Several findings link the beneficial effects of 17α-E2 to effects on brain function. First, 17α-770 
E2 is the predominant form of estradiol expressed in the rodent brain, and has been postulated 771 
to have neuroprotective roles in humans. It has also been reported to confer protection from 772 
oxidative stress, as well as amyloid toxicity associated with Alzheimer’s disease and 773 
Parkinson's disease in animal models347-350. Also, the metabolic and longevity benefits of 17α-774 
E2 may be attributable to effects on the hypothalamus, as treated mice have reduced food 775 
intake, probably due to activation of hypothalamic anorexogenic pathways345,351. 17α-E2 is also 776 
highly anti-inflammatory, both in adipose tissue and in the hypothalamus203,345. In summary, 777 
17α-E2 reduces food intake, possibly mimicking DR, leading to improved metabolic function 778 
and reduced age-associated inflammation, but the mechanisms by which 17α-E2 confers these 779 
effects requires further studies. 780 
 781 
[H1] The Path to Human Intervention 782 
Animal models have been highly successful in generating candidate healthspan interventions, 783 
many of which work in mammals, which raises a question in many researchers’ minds. How 784 
do we test these interventions in humans and accelerate their widespread use to extend our 785 
healthspan? The long lifespan of humans makes direct testing barely feasible. Instead, three 786 
major approaches have been implemented, of which two have been illustrated in prior sections. 787 
A first approach, used most widely, has been to test longevity interventions in the context of 788 
disease indications, including the evaluation of sirtuin-activating compounds in clinical studies 789 
of psoriasis and ulcerative colitis352. Interestingly, these diseases are not naturally linked to 790 
ageing and sirtuin-activating compounds have yet to be clinically approved. Although this is 791 
perhaps the most direct approach, ameliorating ageing is not the same as treating a disease 792 
process, and geropotective drugs will likely act preventatively, rather than as treatments for 793 
age-related conditions. More recent approaches have chosen diseases or processes more closely 794 
linked to ageing, including senolytic approaches to treat osteoarthritis and idiopathic 795 
pulmonary fibrosis, as well as evaluating the use of rapalogs to reverse immunosenescence. 796 
These studies show more promise as they progress toward clinical use. However, whether this 797 
approach is an effective avenue to move interventions toward primary prevention in healthy 798 
people to keep them disease-free and functional for longer has yet to be determined. 799 
A second approach is embodied by the TAME trial with metformin and more directly addresses 800 
the promise of interventions that slow ageing: to prevent multiple chronic diseases 801 
simultaneously. Clinical testing based on ageing itself as an indication is now permitted by the 802 
FDA, and the 2018 version of the World Health Organization's International Classification of 803 
Diseases (ICD-11)  for the first time included an extension code "Ageing-Related" (XT9T) for 804 
ageing-related diseases, thus recognising aging as a major risk factor. The upside of this 805 
approach is that, if successful, a path toward widespread use in at-risk populations can be 806 
readily imagined. The downside is the cost and duration of the study, which will follow over 807 
3000 people for up to three years. Therefore, the approach is cost prohibitive for studies of a 808 
large number of interventions and, given that it is only conjecture to know which will work 809 
best at this stage, other approaches are warranted. The TAME trial is potentially 810 
groundbreaking in ageing research; however, multiple types of interventions should be used at 811 
the beginning of human intervention studies as we learn the best paths forward. 812 
 813 
A third, and promising, approach is only now becoming feasible. Until recently, measurements 814 
of ageing have been limited largely to physiological or functional measures, including walking 815 
speed, pulse wave velocity, VO2 max, and measures of organ function. However, using 816 
artificial intelligence strategies to analyze deep datasets, several molecular biomarkers that can 817 
be generated using non-invasive or minimally invasive strategies have been proposed to 818 
measure biological age. Among these is the epigenetic clock353,354, which integrates DNA 819 
methylation data from over 300 sites in the genome and can be assessed in multiple tissues, 820 
including peripheral blood mononuclear cells. In mice, where a similar clock has also been 821 
elucidated, anti-ageing interventions can delay clock progression355. Other biomarkers have 822 
been proposed, including transcriptomic and metabolomic profiles of blood, complete blood 823 
counts, accelerometry data on iPhones and even facial pattern recognition356. None of these 824 
biomarkers have been fully validated, but they offer great promise. However, there are major 825 
questions: How will these biomarkers respond to longevity interventions? Are they dynamic? 826 
Will interventions slow the rate of clock progression or reverse the clock? How do the different 827 
clocks relate to each other? Do different biomarkers inform on different aspects of the ageing 828 
process? Will it be possible to detect individual differences in the progress of the different 829 
mechanisms of ageing and thus tailor geroprotective interventions? Despite the many 830 
unanswered questions, the discovery of biomarkers and clocks is a major breakthrough that 831 
opens the possibility of using them as primary endpoints in the clinic, if they can be tied to 832 
changes in clinical outcomes. These discoveries may open the way to relatively short-term, 833 
smaller studies that determine which interventions alter which clocks. Human studies using 834 
these biomarkers are only just beginning in earnest. Given that none of them may be validated 835 
by regulatory agencies in the near future, these studies may only be an entry point to identify 836 
interventions with the largest possible impact on ageing, leading to studies like the TAME trial 837 
as a step to clinical approval. 838 
 839 
A final approach is to avoid drugs altogether and develop natural products as supplements to 840 
slow ageing. These compounds are less tightly regulated than are drugs, and many are already 841 
legally marketed as treatments for a wide range of conditions, often without clear clinical 842 
evidence to support their use. In the context of geroprotection, a combination of two 843 
compounds to modulate NAD(+) and sirtuin activity is being marketed and has undergone 844 
limited human testing. Other reagents to enhance NAD(+) levels are also available. This 845 
approach has the advantage of rapidly reaching a large population, but raises important 846 
questions about how marketed products can be safety-tested and experimentally validated. The 847 
natural product market is thus a double-edged sword – quicker to market but less regulated. 848 
These compounds should be tested in scientifically rigorous, placebo-controlled trials, to 849 
demonstrate that the benefits of supplements outweigh any risks and the costs to the consumer. 850 
Can public studies be performed using non-invasive biomarkers? Again, although many 851 
unvalidated products are sold as “anti-ageing,” we are at an early stage in terms of generated, 852 
validated products. 853 
 854 
Ageing is a complex process, and no geroprotective intervention has ameliorated all of its 855 
features, although DR has so far come the closest. Genetic studies in model organisms have 856 
indicated that combinatorial interventions targeting different pathways can be the most 857 
effective in ameliorating ageing357-359. The same is likely to be true of pharmacological 858 
interventions, and indeed combinatorial treatments in yeast360, C. elegans361 and Drosophila362 859 
have been more effective than administration of single agents. The evidence from animal 860 
studies, and our understanding of human ageing, indicate that multiple approaches to 861 
ameliorating the effects of ageing should be pursued in parallel. 862 
 863 
Although human translational studies in ageing are at an early stage, they represent a major 864 
step forward in ageing research. We have yet to understand how achievable or difficult it will 865 
be to lessen the effects of human ageing and what will be the best methods to validate success. 866 
Nevertheless, it is now possible to envision geroprotective strategies to delay the onset of many 867 
debilitating diseases and maintain function later in life.  868 
 869 
[H1] Conclusions 870 
After long and laborious studies on the fundamental drivers of the ageing process, numerous 871 
small molecules have emerged as candidates to delay human ageing, prevent disease onset 872 
and/or progression and maintain human functional capacity later in life. While individual 873 
scientists certainly have their favorite candidates, there is an emerging consensus on what the 874 
best approaches will be. Mild inhibition of the activity of the nutrient-sensing network, 875 
particularly of mTORC1, is a promising strategy and is currently furthest down the road to 876 
clinical validation and delivery. A major challenge will be to identify the most effective targets 877 
for health improvement, which may be tissue-specific and hence require further drug 878 
development, combined with the fewest side-effects, which will require fine-tuning of dose 879 
and timing of drug administration. Senostasis and senolysis are also promising strategies, and 880 
further experimental work in animals and clinical trials are needed to determine the safety and 881 
efficacy of these approaches in humans, and also any potential negative side-effects, especially 882 
in the longer term. Localised, compartment-specific treatment, for instance of arthritic knees, 883 
may be safer and more effective than systemic administration. Although our understanding of 884 
potential geroprotective effects of systemically circulating molecules is in its infancy, the 885 
experimental results with mice strongly encourage further research to understand the 886 
rejuvenating effects. Experimental work on ageing with the microbiome is also in its infancy, 887 
but holds great promise. It is also highly likely that new interventions, better than the ones we 888 
know about today, will emerge. Nevertheless, excitement is rising as interventions begin to be 889 
tested in the clinic, and there is a general expectation that at least some are likely to prove 890 
efficacious in the reasonably short term. 891 
Although a number of challenges remain, including regulatory hurdles, clinical design 892 
questions, incompletely validated biomarkers of human ageing, and commercial challenges to 893 
bring the new interventions to market, it is likely that strong evidence will emerge in the near 894 
future for feasible strategies to delay human ageing. Administering these interventions in a safe 895 
manner that is inclusive of everyone regardless of financial capacity is incumbent, but this 896 
approach could tilt medical treatment away from “sick” care and towards broad spectrum 897 
prevention, a major advance that can revolutionize medicine, maximizing improvement of life 898 
quality and mitigating the soaring costs of age-associated chronic diseases. 899 
  900 
Box 1. Geroprotector inclusion criteria  901 
 902 
A number of agents have been reported to affect ageing in animal models, and in a few cases, 903 
some data exists in humans. Rather than provide a complete list, we have chosen to focus on a 904 
smaller subset, classified as Tier 1 or Tier 2 based on published geroprotector inclusion criteria, 905 
which we have modified as described. 906 
 907 
Primary Inclusion Criteria:  908 
• Increased lifespan in animal models  909 
• Amelioration of Human Biomarkers of Ageing 910 
• Minimal side effects at therapeutic dose 911 
• Reproducibility in multiple species and/or different strains of a mammalian species  912 
• Acceptable toxicity 913 
Secondary Inclusion Criteria 914 
• Evidence for target pathway in ageing, ideally in humans  915 
• Increased stress resistance 916 
• Protection from multiple age-related diseases  917 
 918 
  919 
Box 2. In vivo screening to identify geroprotectors  920 
 921 
Given that ageing studies are long in duration and costly, direct screening for geroprotectors 922 
has been of limited feasibility. Nevertheless, several approaches have led to interesting 923 
candidates. A relatively direct approach performed screens of over 80,000 small molecules for 924 
extension of lifespan in C. elegans when administered in early adulthood363,364. A range of 925 
molecules was identified, including those that resemble serotonin or dopamine, increasing 926 
oxidative stress resistance, or affect several signalling pathways. 927 
 928 
In C. elegans, a separate approach screened for molecules that induce multiple forms of stress 929 
resistance and then tested their effects on lifespan365. Using surrogate phenotypes, such as stress 930 
resistance, can make the screening technique easier, but restricts the classes of molecules 931 
identified. A similar approach was used in yeast, in which a correlation was found between 932 
properties of G1 cell cycle progression and replicative lifespan. FDA-approved compounds 933 
were identified first for the cell cycle effect and then tested for longevity, leading to the 934 
identification of ibuprofen and other molecules252,366. The labour-intensive nature of the yeast 935 
replicative ageing assay has precluded large compound screens, but high-throughput ageing 936 
analysis has recently been developed, opening the way for more comprehensive screens367,368. 937 
 938 
Screens in mammalian cell culture have also been performed in a recent approach identifying 939 
compounds that reduce senescence markers369. Interestingly, the two most potent compounds 940 
identified also robustly extended C. elegans lifespan, pointing once again to the conserved 941 
nature of longevity pathways across species. Despite the difficulty of chemical screens to 942 
identify geroprotectors, this approach has proven fruitful and, with more high throughput 943 
analysis and better surrogate phenotypes to assess, the approach become more widely utilized 944 
in the near future. 945 
 946 
  947 
Box 3. In silico approaches to identify geroprotectors  948 
 949 
In silico approaches have, in general, used structural and genetic information, or a combination 950 
of both, to identify candidate geroprotectors370. Databases such as Digital Aging Atlas371,372, 951 
Human Aging Genomic Resources (HAGR)373,374 and Aging Clusters375, are powerful 952 
repositories of diverse ageing-relevant data. 953 
 954 
Structural approaches 955 
Structural information can be used to find chemical similarities between compounds and hence 956 
candidate geroprotectors. 957 
 958 
Compounds that increase lifespan in C. elegans were identified from DrugAge in HAGR and 959 
in an experimental screen364. Their structures were found using PubChem376,377, 960 
ChemSpider377,378 and the literature. Resulting molecular descriptors were combined with 961 
drug–protein interactions from STITCH379 to identify other candidates for increasing worm 962 
lifespan, one of which, 2-bromo-4’-nitroacetophenone, was experimentally validated380. 963 
 964 
In a different structural approach, 2054 putative ageing genes from 9 model organisms were 965 
identified in GenAge, and 94 were prioritized based on their effect on lifespan. These were 966 
screened against all DrugBank compounds for similarities in ligand-binding structures, 967 
yielding 31 candidates. Several of these were validated as extending lifespan or healthspan in 968 
a rotifer381. A related study associated the gene ontology terms and chemical descriptors for 969 
the protein targets of compounds in DrugAge that extended worm lifespan, to identify related 970 
drugs as candidate geroprotectors, but these were not further validated382. 971 
 972 
Genetic approaches 973 
Changes in gene expression with age, in response to genetic and environmental interventions 974 
that ameliorate ageing, and in response to treatment with drugs or small molecules, have been 975 
used to identify candidate geroprotectors. 976 
 977 
Transcriptional profiles of bone marrow cells from young and old humans were compared with 978 
the profiles from 70 drugs that extended lifespan in C. elegans. Candidates from the overlap 979 
were analysed for their effects on phenotypes of late passage human embryonic lung 980 
fibroblasts, and were enriched for compounds that restored their phenotypes to a younger state 981 
and increased their long-term survival383. 982 
 983 
Several studies have been based upon age-related changes in gene expression in human tissues, 984 
from the GTEx database. Age-related changes in gene expression in ageing human brain were 985 
combined with data from the Connectivity Map to identify 24 small molecule candidates, a 986 
group that was significantly enriched for compounds that had already been shown to extend 987 
lifespan in worms or fruit flies384. In a closely related approach, changes in gene expression 988 
with age in multiple tissues were combined and used to identify small molecules in the 989 
Connectivity Map that shifted the transcriptional profile towards a ‘young’ one, and identified 990 
31 candidates that were significantly enriched for known geroprotectors and for novel 991 
compounds that extended lifespan in C. elegans385. Similarly, expression profiles from young 992 
and old human adipose tissue were used to calculate gene co-expression networks, and the 993 
Connectivity Map was then interrogated for small molecules that reversed the age-associated 994 
changes386. 995 
 996 
In a broader use of genetic information, ageing-related gene products in humans from Aging 997 
Clusters were combined with their interactions with compounds in STITCH and DrugBank. 19 998 
compounds were enriched for ageing-related targets, 6 of which were already shown to have 999 
pro-longevity properties in animal models, a significant enrichment. Tanespimycin, an 1000 
inhibitor of HSP90, was the top-ranked novel candidate, and was shown to increase lifespan in 1001 
C. elegans through its HSP90 target387 (FIG. 4c). 1002 
 1003 
Gene expression profiles from rat cells exposed to sera from dietarily restricted rats or rhesus 1004 
monkeys were used to identify 39 genes that had human orthologs, and these were compared 1005 
to gene expression changes in Connectivity Map388, a database of expression profiles from a 1006 
panel of human cell lines responding to treatment by drugs and unlicensed small 1007 
molecules389,390. Profiles from 11 of the 39 candidate drugs mimicked those of dietary 1008 
restriction, and three of these— rapamycin, LY-294002 and trichostatin A — had already been 1009 
shown to increase lifespan in C. elegans (see section on rapamycin and mTOR inhibition). 1010 
These three candidates and allantoin increased normal worm lifespan and rescued the age-1011 
related decline in pharyngeal pumping391. 1012 
  1013 
Box 4. The National Institute on Aging Interventions Testing Program (ITP)  1014 
 1015 
The ITP392 tests the potential of interventions delivered in the diet to promote healthy ageing. 1016 
Both sexes of a genetically variable population of mice, the result of a 4-way cross among 1017 
inbred strains, are evaluated in 3 different centres (Jackson Laboratory, University of Texas 1018 
Health Science Center, and University of Michigan), at numbers sufficient to detect a 10% 1019 
increase in lifespan with 80% power. The three testing sites use standardized operating 1020 
procedures, including diets, caging, bedding and mouse handling. Interventions for testing are 1021 
proposed by the research community through an annual call for proposals, and tested 1022 
compounds have ranged from drugs and dietary supplements to micronutrients and metabolic 1023 
intermediates47. 1024 
 1025 
Positive Findings from the ITP 1026 
 1027 
Acarbose (see main text) – Increased lifespan in both males and females (the effects were 1028 
greater in males) when initiated at 4 months of age201. When initiated at 16 months of age, 1029 
overall lifespan was extended only in males, but maximum lifespan was extended in both 1030 
sexes344. 1031 
Aspirin (see main text) – Increased lifespan in males but not females248. A later study failed 1032 
to replicate lifespan extension with higher doses331.  1033 
Glycine (see main text) – Increased median and maximum lifespan in males and females331. 1034 
Nordihydroguaiaretic acid – Increased mean lifespan in males but not females248, even at 1035 
doses that gave equivalent blood levels in males and females201. 1036 
Protandim® – Increased lifespan in males but not females344. 1037 
Rapamycin (see main text) – Increased mean and maximum lifespan in both males and 1038 
females when initiated at 20 months of age46 or at 9 months of age47. Females responded more 1039 
robustly than males at equivalent doses and blood levels of rapamycin were greater in females; 1040 
when ~equal blood levels were achieved, the response of lifespan was about equivalent in 1041 
females and males47. 1042 
17α-Estradiol (see main text) – Increased lifespan in males but not females, at 4.8 ppm dose201 1043 
and 14.4 ppm dose344. 1044 
 1045 
Negative findings from the ITP 1046 
Curcumin 1047 
Fish oil 1048 
Green tea extract 1049 
HBX (2‐(2‐hydroxyphenyl) benzothiazole) 1050 
INT-767 (an FXR and TGR5 agonist) 1051 
Inulin 1052 
Medium-chain triglyceride oil 1053 
Metformin 1054 
Methylene blue 1055 
Nitroflurbiprofen 1056 
Oxaloacetic acid 1057 
Resveratrol 1058 
Simvastatin 1059 
TM441, a pan-inhibitor of PAI-1 1060 
Ursodeoxycholic acid 1061 
Ursolic acid 1062 
4-OH-α-phenyl-N-tert-butyl nitrone  1063 
Figure 1. Age composition of the population and incidence of major age-related diseases. 1064 
Changes in the age composition of the global human population over time, showing the decline 1065 
in 0-15-year-olds and the increase in 65+year-olds. Plotted from data in 1066 
https://population.un.org/wpp/DataQuery (panel a). The incidence of three major age-related 1067 
diseases, dementias, cardiovascular disease and neoplasms, in two low (Afghanistan and 1068 
Ethiopia), two middle (India and Brazil) and two high (Japan and Switzerland) income 1069 
countries. Rates are normalized to incidence at age 20 (cardiovascular disease and neoplasms) 1070 
or age 40 (dementias) for each country because of the strong relationship between overall 1071 
incidence rate and average income, indicating variation in rates of diagnosis. Plotted from data 1072 
in the Global burden of Disease Study 2017 http://ghdx.healthdata.org/gbd-2017. (panel b). 1073 
 1074 
Figure 2. Agents and their influence on different hallmarks of ageing. Geroprotective 1075 
agents, small molecules and metabolites ameliorate one or more of the hallmarks of ageing to 1076 
prevent ageing-related decline in function and ageing-related diseases. *Impaired protein 1077 
homeostasis also includes autophagy. 1078 
 1079 
Figure 3. Effects of rapamycin and inhibition of mTORC1. Inputs to and outputs from 1080 
mTORC1 (panel a). In the process of macroautophagy, damaged organelles and other cellular 1081 
components are accumulated in a double-membrane-enclosed autophagosome, which fuses 1082 
with a lysosome and releases its contents for degradation and recycling (panel b). 1083 
Figure 4. Some of the modes of action for senolytics. BCL2 proteins, which inhibit 1084 
mitochondrial activation of apopotosis, are elevated in senescent cells and their inhibition 1085 
selectively induces apoptosis in these cells (panel a). A FOXO4 peptide disrupts the association 1086 
of FOXO4 with p53 leading to p53 nuclear exclusion and cellular apoptosis (panel b). The 1087 
molecular chaperone HSP90 stabilizes phosphorylated AKT (pAKT), which is elevated in 1088 
senescent cells and protects them against apoptosis. Inhibition of HSP90 destabilizes pAKT 1089 
resulting in selective apoptosis of the senescent cells (panel c). Cardiac glycosides disrupt the 1090 
Na+/K+ ATPase pumps in the plasma membrane, leading to lowering of pH in senescent cells, 1091 
which already have a low pH, thus rendering them vulnerable to apoptosis (panel d). 1092 
  1093 
Glossary terms 1094 
Healthspan: the time in a person's life when they are in general good health. 1095 
Immunosenescence: Decline in function of the immune system with age. 1096 
Senostatics: Chemicals that prevent senescent cells from producing the senescence associated 1097 
secretory phenotype (SASP), which can damage surrounding tissue and cause systemic 1098 
inflammation. 1099 
Dietary Restriction (DR): Reduced food intake from its voluntary level while avoiding 1100 
malnutrition. 1101 
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